French drugs agency suspends new Carmat artificial heart implants

heart healthy istock

France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

A spokeswoman said that the agency had requested further information from the company following the patients death, which was first reported by Europe 1 radio. The company was not immediately available for comment.

More on this...

Carmat has not generated any significant revenue but is closely followed by investors as heart diseases represent a leading cause of death worldwide and its devices could represent a major medical breakthrough if proven reliable.